In the case group, patients with age over 40 years accounted for 83.01%; 75.28% patients were positive in estrogen receptor (ER+) and 76.41% were positive in progesterone receptor (PR+); 91.85% patients were in clinical stage I or II, and 8.15% (58 cases) were in stage III or IV; 377 cases (52.94%) had lymph node metastasis (Table 3). The gene discussed is ESR1; the disease is metastatic malignant neoplasm in the lymph nodes.